This statistic depicts the value of filgrastim sales from Neupogen compared to its U.S. biosimilar competitors from 2015 to 2017. In 2015, Neupogen generated 810.05 million dollars in sales in the United States. As of November 2017, Neupogen sales decreased to 400.2 million U.S. dollars.
Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017
(in million U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Association for Accessible Medicines, & IQVIA. (February 13, 2018). Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017 (in million U.S. dollars) [Graph]. In Statista. Retrieved December 21, 2024, from https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/
Association for Accessible Medicines, und IQVIA. "Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017 (in million U.S. dollars)." Chart. February 13, 2018. Statista. Accessed December 21, 2024. https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/
Association for Accessible Medicines, IQVIA. (2018). Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017 (in million U.S. dollars). Statista. Statista Inc.. Accessed: December 21, 2024. https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/
Association for Accessible Medicines, and IQVIA. "Sales of Neupogen Compared to Its U.S. Biosimilars from 2015 to 2017 (in Million U.S. Dollars)." Statista, Statista Inc., 13 Feb 2018, https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/
Association for Accessible Medicines & IQVIA, Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017 (in million U.S. dollars) Statista, https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/ (last visited December 21, 2024)
Sales of Neupogen compared to its U.S. biosimilars from 2015 to 2017 (in million U.S. dollars) [Graph], Association for Accessible Medicines, & IQVIA, February 13, 2018. [Online]. Available: https://www.statista.com/statistics/869910/neupogen-sales-loss-to-biosimilars/
